Selective inhibition of α(1b)-adrenergic receptor expressions and function using a phosphorothioate antisense oligodeoxynucleotide

Molecular Pharmacology

Volumn 53, Issue 6, 1998, Pages 1034-1039

  Gonzalez Cabrera, Pedro J ^a   Iversen, Patrick L ^b,c   Liu, Marvin F ^a   Scofield, Margaret A ^a   Jeffries, William B ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1B ADRENERGIC RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; HISTAMINE; INOSITOL PHOSPHATE; NAPHAZOLINE; NORADRENALIN; PRAZOSIN; TRITIUM; ALPHA 1 ADRENERGIC RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; NUCLEOTIDE; PHOSPHATIDYLINOSITOL;

AMINO ACID TRANSPORT; ANIMAL CELL; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BETA ADRENERGIC STIMULATION; GENE EXPRESSION REGULATION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; RECEPTOR AFFINITY; RECEPTOR DENSITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DRUG ANTAGONISM; HYDROLYSIS; METABOLISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; RADIOASSAY;

HYDROLYSIS; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATIDYLINOSITOLS; POLYMERASE CHAIN REACTION; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, ALPHA-1; THIONUCLEOTIDES;

EID: 0031595988     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Beltinger C, Saragovi HU, Smith RM, LcSauteur L, and Shan N (1995) Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814-1823.
2. Berridge MJ, Dawson RMC, Downes P, Heslop JP, and Irvine RF (1983) Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J 212:473-484.
3. Bilsky EJ, Bernstein RN, Hruby VJ, Rothman RB, Lai J, and Porreca F (1996) Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptors in vivo. J Pharmacol Exp Ther 277:491-501.
4. Buckner SA, Oheim KW, Morse PA, Knepper SM, and Hancock AA (1995) Adrenoceptor-induced contractility in rat aorta is mediated by the alpha (1D) subtype. Eur J Pharmacol 297:241-248.
5. Crooke RM (1991) In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des 6:609-646.
6. Desjardins JP and Iversen PL (1995) Inhibition of the rat cytochrome P450-3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. J Pharmacol Exp Ther 275:1608-1613.
7. 1 MF2 cells: Evidence for high affinity binding to a functional histamine H-1 receptor. Eur J Pharmacol 268:257-262.
8. 1C subtype. Mol Pharmacol 45:703-708.
9. 1-adrenoceptors: Subtypes, signal transduction and regulation. Pharmacol Res Commun 6:53-60.
10. Gewirtz AM, Stein CA, and Glazer PM (1996) Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc Natl Acad Sci USA 93:3161-3163.
11. 1-adrenoceptor. Eur J Pharmacol 151:333-335.
12. Hawley P and Gibson I (1996) Interaction of oligodeoxynucleotides with mammalian cells. Antisense Nucleic Acid Drug Dev 6:185-195.
13. 1-adrenoceptors irrespective of the subtype. Mol Pharmacol 52:764-770.
14. Hunter JA, Leslie RA, Gloger IS, and Lawrence M (1995) Probing the function of novel genes in the nervous system: Is antisense the answer? Trends Neurosci 18:329-331.
15. Iversen PL, Zhu S, Meyer A, and Zon G (1992) Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into culture cells. Antisense Res Dev 2:211-222.
16. Jeffries WB, Yang E, and Pettinger WA (1988) Renal alpha-1 adrenergic receptor response coupling in spontaneously hypertensive rats. Hypertension 12:80-88.
17. Krieg AM and Stein CA (1995) Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein? Antisense Res Dev 5:241.
18. 1B-adrenergic receptor subtypes. Mol Pharmacol 52:1010-1018.
19. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:264-275.
20. 2C-adrenoceptors in rat striatum following antisense oligodeoxynucleotide infusion. Mol Brain Res 47:267-274.
21. Minneman KP, Han C, and Abel PW (1988) Comparison of alpha-1-adrenergic receptor subtypes distinguished by chloroethylclonidine and WB-401. J Pharmacol Exp Ther 33:509-514.
22. 1A-subtype. Mol Pharmacol 46:823-831.
23. Phillips JA, Craig SJ, Bayley D, Christian RA, Geary R, and Nicklin PL (1997) Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 54:657-668.
24. Piascik MT, Guarino RD, Smith MS, Soltis EE, Saussy Jr-DL, and Perez DM (1995) The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. J Pharmacol Exp Ther 275:1583-1589.
25. Piascik MT, Hrometz SL, Edelmann SE, Guarino RD, Hadley RW, and Brown RD (1997) Immunocytochemical localization of the alpha-1E adrenergic receptor and the contribution of this and the other subtypes to vascular smooth muscle contraction: Analysis with selective ligands and antisense oligonucleotides. J Pharmacol Exp Ther 283:854-868.
26. 1-adrenergic receptor subtype classification. Mol Pharmacol 46:221-226.
27. Scofield MA, Liu F, Abel PW, and Jeffries WB (1995) Quantification of steady state expression of mRNA for alpha-1 adrenergic receptor subtypes using reverse transcription and a competitive polymerase chain reaction. J Pharmacol Exp Ther 275:1035-1042.
28. Stein CA, and Cheng YC (1993) Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science (Washington DC) 261:1004-1012.
29. Wahlestedt C, Pich EM, Koob GF, Yee F, and Heilig M (1993) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science (Washington DC) 259:528-531.
30. 1-adrenoceptor subtypes by chloroethylclonidine. Eur J Pharmacol, in press.
31. Zamecnik PC and Stephenson ML (1978) Inhibition of Rous Sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75:280-284.
32. 2 dopamine receptors in mouse striatum. J Pharmacol Exp Ther 268:1015-1023.